アデノシンA1受容体媒介の陽性アロステリックメカニズム
Christopher J Draper-Joyce1,2, Rebecca Bhola3, Jinan Wang4
1Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Nature
|September 9, 2021
まとめ
この研究では,アデノシンA1受容体 (A1R) の新しいアロステリック調節剤MIPS521が導入され,ラットにおける非オピオイド性疼痛緩和効果が実証されました. ニューロパシー疼痛の標的治療の開発のための新しい戦略を強調しています.
科学分野:
- 薬理学について
- 神経科学
- 構造生物学
背景:
- アデノシンA1受容体 (A1R) は神経疾患の痛みに対する非オピオイド鎮痛剤の潜在的な標的である.
- 前回のオーステリックA1Rアゴニストの試みは,選択性や副作用が悪かったため失敗した.
研究 の 目的:
- A1Rの陽性アロステリック調節剤であるMIPS521の神経疾患の痛み緩和効果を調査する.
- MIPS521によるA1R変調の構造的基礎を解明する.
主な方法:
- ネオロパシー疼痛のラットモデルでのin vivo鎮痛効果試験
- A1R-アデノシン-MIPS521-Gi2複合体の構造を決定するX線結晶学.
- 分子ダイナミクスシミュレーションと 運動結合実験
主要な成果:
- MIPS521は,内生性アデノシン濃度を調節することによって,神経疾患の痛みを持つラットにおいて鎮痛効果を示した.
- 結晶構造はMIPS521の新しいアロステリック結合部位を明らかにした.
- MIPS521はA1R-アデノシン-Gi2複合体を安定させることが示された.
結論:
- MIPS521は,病気の状況に特化した非オピオイド鎮痛剤の開発に有望な先駆けとなります.
- 構造に基づくアロステリック薬の設計は,A1Rをターゲットにするための実行可能な戦略を提供します.
- この研究は,A1Rを調節する痛みの治療法の将来の開発のための基盤を提供します.
関連する概念動画
Adrenergic Receptors: ɑ Subtype
2.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.3K
Analgesia and Pain Management
954
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
954
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.1K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.1K
Adrenergic Receptors (Adrenoceptors): Classification
3.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
3.7K
Adrenergic Agonists: Indirect-Acting Agents
2.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.1K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.2K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.2K


